CCB: Genomics


An immensely complex molecular network of interactions forms the foundation of human biology and disease. Genomic approaches provide a particularly illuminating window to biological systems, and when combined with advanced analysis allow us to learn and model this complexity. The goal of CCB Genomics research is to interpret and distill this complexity through accurate analysis and modeling of molecular pathways, particularly those in which malfunctions lead to the manifestation of disease. We are inventing integrative methods for systems-level pathway modeling through integrative analysis of genome-scale datasets. We apply these approaches in studying challenging biological problems, such as how pathways function in diverse cell types and how they change dynamically, for instance during cellular differentiation or in response to genetic and pharmacological perturbations. Read more here.

Deputy Director

Olga TroyanskayaOlga Troyanskaya became deputy director for genomics in 2014 after working with CCB (formerly SCDA) as a consultant since 2013. Troyanskaya is also a professor at the Lewis-Sigler Institute for Integrative Genomics and in the department of computer science at Princeton University, where she has been on the faculty since 2003. At Princeton, she runs the Laboratory for Bioinformatics and Functional Genomics. She holds a Ph.D. in biomedical informatics from Stanford University. Troyanskaya is a recipient of the Sloan Research Fellowship, the National Science Foundation CAREER award, the Overton Prize from the International Society for Computational Biology, and the Ira Herskowitz Award from the Genetics Society of America. Contact Olga otroyanskaya(replace this with the @ sign)

Open Positions

Research scientist and postdoctoral fellow positions: Develop sophisticated computational approaches to advance biomedical research and tackle complex human disease. Projects at the intersection of big data analysis, machine learning and functional genomics, with opportunities for close collaborations with experimentalists and high-impact clinical researchers.

Click here for more details.